脓毒症患者循环外泌体对T细胞功能的影响
该研究从广东省人民医院急诊ICU 10例脓毒症患者血浆中经超速离心提取循环外泌体(EXO),用透射电镜、NTA和Western blotting鉴定;另取5名健康志愿者外周血分离PBMC、磁珠分选原代T细胞体外扩增。用0、1、2.5、5、10 mg/L脓毒症患者循环EXO干预24小时后,CCK-8检测T细胞活性、流式细胞术检测CD69、CD25、CD4+ T细胞PD-1及Treg比例。结果示脓毒症患者循环EXO水平高于健康对照(48.78±5.14 vs. 22.18±2.25 mg/L,P<0.01);5 mg/L干预24小时T细胞活性开始受抑(85.84±0.56% vs. 100.00±0.00%,P<0.05),10 mg/L时显著受抑(72.44±2.36% vs. 100.00±0.00%,P<0.01);CD69降低、PD-1升高、Treg比例升高,CD25无显著变化。作者认为脓毒症循环EXO诱导T细胞功能障碍,可能是脓毒症免疫抑制的新机制。
要点
- 脓毒症患者循环EXO水平为48.78±5.14 mg/L,高于健康对照的22.18±2.25 mg/L(P<0.01)。
- 5 mg/L脓毒症患者血浆EXO干预24小时,T细胞活性降至(85.84±0.56)%,低于对照的(100.00±0.00)%(P<0.05)。
- 10 mg/L脓毒症患者血浆EXO干预24小时,T细胞活性降至(72.44±2.36)%,低于对照的(100.00±0.00)%(P<0.01)。
- 脓毒症患者血浆EXO干预后T细胞CD69降至(52.87±1.29)%,低于健康对照的(67.13±3.56)%(P<0.05)。
- 脓毒症患者血浆EXO干预后CD4+ T细胞PD-1升至(57.73±3.06)%、Treg比例升至(54.67±1.19)%,均高于健康对照(分别为32.07±0.22%、24.60±3.51%,P<0.01);CD25无显著变化(P>0.05)。
适用人群与场景
- 广东省人民医院急诊重症监护病房收治的10例脓毒症患者,取其血浆提取循环外泌体。
- 5名健康志愿者外周血分离PBMC、磁珠分选原代T细胞体外扩增,作为对照来源。
研究设计与关键结果
- 研究类型为体外实验:超速离心法从10例脓毒症患者血浆提取EXO,经透射电镜、NTA和Western blotting鉴定标志物确认分离成功。
- 脓毒症患者循环EXO表达水平高于健康对照组(mg/L:48.78±5.14 vs. 22.18±2.25,P<0.01)。
- 5 mg/L脓毒症患者血浆EXO干预T细胞24小时后,T细胞活性开始受抑[(85.84±0.56)% vs.(100.00±0.00)%,P<0.05]。
- 随剂量增加,10 mg/L EXO干预24小时后T细胞活性显著受抑[(72.44±2.36)% vs.(100.00±0.00)%,P<0.01]。
- 与健康对照组相比,脓毒症患者血浆EXO干预后T细胞早期活化标志物CD69表达显著降低[(52.87±1.29)% vs.(67.13±3.56)%,P<0.05]。
- 脓毒症患者血浆EXO干预后T细胞PD-1表达上调[(57.73±3.06)% vs.(32.07±0.22)%,P<0.01],Treg比例升高[(54.67±1.19)% vs.(24.60±3.51)%,P<0.01]。
- 晚期活化标志物CD25表达保持稳定[(84.77±3.44)% vs.(85.93±2.32)%,P>0.05]。
证据类型、等级与局限
- 证据类型:体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为脓毒症患者循环EXO诱导T细胞功能障碍,可能是脓毒症免疫抑制的新机制。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effect of circulating exosomes (EXO) on T cell function in patients with sepsis.
METHODS: Plasma EXO were obtained by ultracentrifugation from 10 patients with sepsis admitted to the emergency intensive care unit of Guangdong Provincial People's Hospital Affiliated to Southern Medical University. Transmission electron microscopy observation, nanoparticle tracking analysis (NTA), and Western blotting were used to detect EXO markers to identify their characteristics. Furthermore, peripheral blood mononuclear cells (PBMC) were isolated from the peripheral blood of 5 healthy volunteers, primary T cells were sorted by magnetic beads and expanded in vitro. After 24 hours of intervention with different doses (0, 1, 2.5, 5, 10 mg/L) of circulating EXO in patients with sepsis, T-cell activity was assessed using a cell counting kit-8 (CCK-8). The expression of T cell activation indicators CD69 and CD25 were observed using flow cytometry. Additional evaluations were performed on immunosuppressive indicators including the expression of programmed cell death 1 (PD-1) in CD4+ T cells and the proportion of regulatory T cell (Treg).
RESULTS: The identification results confirmed that the successful isolation of EXO from the plasma of sepsis patients. The expression level of circulating EXO in sepsis patients was higher than that in healthy control group (mg/L: 48.78±5.14 vs. 22.18±2.25, P < 0.01). After 24 hours of intervention with 5 mg/L of plasma EXO from sepsis patients, T cells activity began to show suppression [(85.84±0.56)% vs. (100.00±0.00)%, P < 0.05]. As the dosage increased, after 24 hours of intervention with 10 mg/L of EXO, T cells activity was significantly suppressed [(72.44±2.36)% vs. (100.00±0.00)%, P < 0.01]. Compared with the healthy control group, after T cells intervention with plasma EXO from sepsis patients, the expression of early activation marker CD69 was significantly reduced [(52.87±1.29)% vs. (67.13±3.56)%, P < 0.05]. Meanwhile, there was an upregulation of PD-1 expression in T cells [(57.73±3.06)% vs. (32.07±0.22)%, P < 0.01] and an increase in the proportion of Treg [(54.67±1.19)% vs. (24.60±3.51)%, P < 0.01]. However, the expression of the late activation marker CD25 remained stable [(84.77±3.44)% vs. (85.93±2.32)%, P > 0.05].
CONCLUSIONS: Circulating EXO in sepsis patients induce T cell dysfunction, which may be a novel mechanism lead to immunosuppression in sepsis.
参考来源
- Huang J, Huang G, Zhang C, et al. [Effect of circulating exosomes in patients with sepsis on T cell function]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37366123. doi:10.3760/cma.j.cn121430-20230228-00122
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。